RESIST-TB Webinar: Preliminary Results of the endTB-Q Trial for Fluoroquinolone-, Rifampin-Resistant TB

10 January 2025

RESIST-TB will host a webinar on 16 January 2025 to present the preliminary results of the endTB-Q trial.

endTB-Q was an randomized, controlled trial of a stratified medicine strategy using bedaquiline (B), clofazimine (C ), delamanid (D), and linezolid (L) for 9 months in people with extensive TB disease at baseline or delayed culture conversion and for 6 months in people with limited TB disease at baseline and early culture conversion. The control arm was 18-month individualized regimens containing new and repurposed drugs selected in alignment with WHO Guidelines and delivered for the full treatment duration. The trial was implemented at sites in India, Kazakhstan, Lesotho, Pakistan, Peru, and Vietnam.

Register for the webinar here.

Source: RESIST-TB